Glaukos (NYSE:GKOS) COO Joseph Gilliam Sells 10,498 Shares of Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 10,498 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the completion of the transaction, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Stock Performance

Glaukos stock opened at $124.29 on Tuesday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78. The firm has a market cap of $7.14 billion, a P/E ratio of -80.71 and a beta of 0.67. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $111.25 and a 200-day moving average of $96.29.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.Glaukos’s quarterly revenue was up 38.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.28) EPS. Sell-side analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Glaukos

Institutional investors and hedge funds have recently made changes to their positions in the business. UMB Bank n.a. boosted its position in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares in the last quarter. REAP Financial Group LLC purchased a new position in Glaukos during the third quarter valued at $40,000. Park Place Capital Corp raised its stake in Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 162 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Glaukos by 111.4% in the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 215 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in shares of Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 633 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GKOS. Truist Financial boosted their price objective on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Piper Sandler reissued an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research note on Wednesday, January 14th. BTIG Research reaffirmed a “buy” rating and set a $116.00 price objective on shares of Glaukos in a research report on Friday, January 2nd. Wells Fargo & Company upped their target price on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Finally, Stifel Nicolaus increased their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $131.38.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.